Related references
Note: Only part of the references are listed.The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer
Alexander C. Leeksma et al.
FRONTIERS IN ONCOLOGY (2021)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
Luca Malcovati et al.
BLOOD (2020)
Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome
Panagiotis T. Diamantopoulos et al.
ANNALS OF HEMATOLOGY (2019)
Potent ribonucleotide reductase inhibitors: Thiazole-containing thiosemicarbazone derivatives
Merve Ertas et al.
ARCHIV DER PHARMAZIE (2019)
SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
Rami S. Komrokji et al.
BLOOD (2019)
Structure-guided design of anti-cancer ribonucleotide reductase inhibitors
Tessianna A. Misko et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2019)
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations
Andrea Pellagatti et al.
BLOOD (2018)
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia
Yusuke Shiozawa et al.
NATURE COMMUNICATIONS (2018)
Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism
Nikolaos Tsesmetzis et al.
CANCERS (2018)
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Mukundan Baskar Mannargudi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
James A. Kennedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma
L. Dai et al.
ONCOGENE (2017)
Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule
Md. Faiz Ahmad et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
Morihiko Sagawa et al.
CLINICAL CANCER RESEARCH (2017)
The EpiTect Methyl qPCR Assay as novel age estimation method in forensic biology
Shakhawan K. Mawlood et al.
FORENSIC SCIENCE INTERNATIONAL (2016)
Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells
Jian-Ru Guo et al.
SCIENTIFIC REPORTS (2016)
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials
Seongseok Yun et al.
CLINICAL EPIGENETICS (2016)
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
Hetty E. Carraway
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells
H. Dolatshad et al.
LEUKEMIA (2015)
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies
Y. Aye et al.
ONCOGENE (2015)
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
A. Valencia et al.
LEUKEMIA (2014)
Ribonucleotide reductases: essential enzymes for bacterial life
Eduard Torrents
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2014)
First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer
Gideon M. Blumenthal et al.
CLINICAL CANCER RESEARCH (2013)
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia
Josephine Aimiuwu et al.
BLOOD (2012)
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
M. J. Walter et al.
LEUKEMIA (2011)
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
Lanlan Shen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
Ying Jiang et al.
BLOOD (2009)
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
Maria E. Figueroa et al.
BLOOD (2009)
Global increase in DNA methylation in patients with myelodysplastic syndrome
D. Roemermann et al.
LEUKEMIA (2008)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Share Paper
